切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2021, Vol. 15 ›› Issue (12) : 928 -932. doi: 10.3877/cma.j.issn.1674-0785.2021.12.003

临床研究

阿替普酶静脉溶栓前应用依达拉奉对急性脑梗死患者的疗效及脑出血转化的研究
吴有林1, 祝秀蓉1, 梁世福1, 吴文斌2,()   
  1. 1. 611230 四川崇州,崇州市人民医院神经内科
    2. 610072 成都,四川省医学科学院 四川省人民医院神经内科
  • 收稿日期:2021-07-01 出版日期:2021-12-15
  • 通信作者: 吴文斌
  • 基金资助:
    四川省卫健委科研课题项目(18PJ338)

Edaravone before intravenous thrombolysis with alteplase for patients with acute cerebral infarction: Efficacy and impact on transformation of cerebral hemorrhage

Youlin Wu1, Xiurong Zhu1, Shifu Liang1, Wenbin Wu2,()   

  1. 1. Department of Neurology, Chongzhou people's Hospital, Chongzhou 611230, China
    2. Department of Neurology, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, Chengdu 610072, China
  • Received:2021-07-01 Published:2021-12-15
  • Corresponding author: Wenbin Wu
引用本文:

吴有林, 祝秀蓉, 梁世福, 吴文斌. 阿替普酶静脉溶栓前应用依达拉奉对急性脑梗死患者的疗效及脑出血转化的研究[J/OL]. 中华临床医师杂志(电子版), 2021, 15(12): 928-932.

Youlin Wu, Xiurong Zhu, Shifu Liang, Wenbin Wu. Edaravone before intravenous thrombolysis with alteplase for patients with acute cerebral infarction: Efficacy and impact on transformation of cerebral hemorrhage[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(12): 928-932.

目的

探讨阿替普酶静脉溶栓前应用依达拉奉对急性脑梗死患者的疗效及脑出血转化的影响。

方法

收集2018年2月至2019年10月崇州市人民医院治疗的急性脑梗死患者100例,将其按随机表法分为观察组与对照组,各50例。观察组给以阿替普酶溶栓前联合应用依达拉奉治疗,对照组单独使用阿替普酶溶栓治疗。2组患者均于溶栓后继续给予依达拉奉治疗。比较2组患者溶栓前、溶栓后即刻、溶栓后24 h和溶栓后7天的美国国立卫生研究院卒中量表(NIHSS)评分;溶栓前和溶栓后24 h血浆D-二聚体和超敏C反应蛋白(hs-CRP)水平;外周血miRNA-24和miRNA-223表达;溶栓后10天和溶栓后90天改良Rankin量表(mRS)评分;溶栓后24 h脑出血转化率。

结果

2组患者溶栓后即刻、24 h和7天NIHSS评分较溶栓前降低(P均<0.05);观察组溶栓后即刻、24 h和7天NIHSS评分低于对照组(P均<0.05)。2组溶栓后24 h血浆D-二聚体和hs-CRP水平较溶栓前降低(P<0.05);观察组溶栓后24 h血浆D-二聚体和hs-CRP水平低于对照组(P<0.05)。2组溶栓后24 h外周血miRNA-24表达升高,而miRNA-223表达降低;观察组溶栓后24 h外周血miRNA-24表达高于对照组,而miRNA-223表达低于对照组(P<0.05)。观察组溶栓后10天和溶栓后90天mRS评分低于对照组(P<0.05)。2组溶栓后24 h脑出血转化率比较,差异无统计学意义(P>0.05)。

结论

阿替普酶静脉溶栓前应用依达拉奉对急性脑梗死患者的疗效良好,可降低脑出血转化,且可上调miRNA-24表达和下调miRNA-223表达。

Objective

To investigate the efficacy of edaravone before intravenous thrombolysis with alteplase in patients with acute cerebral infarction and the impact on the transformation of cerebral hemorrhage.

Methods

A total of 100 patients with acute cerebral infarction at Chongzhou People's Hospital from February 2018 to October 2019 were collected, and they were randomly divided into an observation group and a control group, with 50 cases in each group. The observation group was treated with alteplase combined with edaravone before thrombolysis, and the control group was treated with alteplase alone. Both groups continued to be treated with edaravone after thrombolysis. We compared National Institutes of Health Stroke Scale (NIHSS) scores before thrombolysis, immediately after thrombolysis, 24 hours after thrombolysis, and 7 days after thrombolysis; plasma D-dimer and high sensitive C-reactive protein (hs-CRP) levels; and the expression of miRNA-24 and miRNA-223 in peripheral blood before and 24 hours after thrombolysis; modified Rankin scale (mRS) scores at 10 and 90 days after thrombolysis; and the transformation rate of cerebral hemorrhage 24 h after thrombolysis between the two groups.

Results

The NIHSS scores immediately, 24 h, and 7 days after thrombolysis were significantly lower than those before thrombolysis in both groups (P<0.05 each); the NIHSS scores of the observation group immediately, 24 h, and 7 days after thrombolysis were significantly lower than those of the control group (P<0.05 each). The plasma D-dimer and hs-CRP level at 24 h after thrombolysis were significantly lower than those before thrombolysis in both groups (P<0.05); the plasma D-dimer and hs-CRP levels at 24 h after thrombolysis were significantly lower than those of the control group (P<0.05). The expression of miRNA-24 in peripheral blood at 24 h after thrombolysis was increased in both groups, while the expression of miRNA-223 was decreased; the changes in the expression of miRNA-24 and miRNA-223 in peripheral blood were more significant in the observation group than in the control group (P<0.05). The mRS scores at 10 and 90 days after thrombolysis were significantly lower in the observation group than in the control group (P<0.05). There was no significant difference in intracerebral hemorrhage transformation of the two groups at 24 h after thrombolysis (P>0.05).

Conclusion

Edaravone before intravenous thrombolysis of alteplase has good efficacy in patients with acute cerebral infarction, and can reduce the transformation of cerebral hemorrhage, up-regulate the expression of miRNA-24, and down-regulate the expression of miRNA-223.

表1 2组急性脑梗死患者溶栓前后NIHSS评分比较(分,
xˉ
±s
表2 2组急性脑梗死患者溶栓前后24 h血浆D-二聚体和hs-CRP水平比较(
xˉ
±s
表3 2组急性脑梗死患者溶栓前后24 h外周血miRNA-24和miRNA-223表达比较(
xˉ
±s
表4 2组急性脑梗死患者溶栓后mRS评分比较(分,
xˉ
±s
表5 2组急性脑梗死患者溶栓后24 h脑出血转化率比较[例(%)]
1
蔡珍飞, 吴肖萍, 曹丹. 2017年台州地区急性脑梗死发生的流行特征 [J]. 实用预防医学, 2019, 26(10): 1247-1250.
2
Sun Z, Xu Q, Gao G, et al. Clinical observation in edaravone treatment for acute cerebral infarction [J]. Niger J Clin Pract, 2019, 22(10): 1324-1327.
3
Liu Y, Yang J, Jiang PP, et al. DAPT score: predictive model of dual-antiplate therapy for acute cerebral infarction [J]. Neurol Sci, 2021, 42(2): 681-688.
4
刘瑞东, 武玉秀. 低剂量阿替普酶静脉溶栓在急性脑梗死患者治疗中的应用价值 [J]. 血栓与止血学, 2020, 26(5): 792-793.
5
王焱浩, 魏小青, 杜炜, 等. 阿替普酶与尿激酶治疗急性轻型脑梗死的疗效及安全性分析 [J]. 中国实用神经疾病杂志, 2021, 24(6): 487-492.
6
中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2014 [J]. 中华神经科杂志, 2015, 48(4): 246-257.
7
周宇艺, 夏桂丽. MRI联合CT灌注成像诊断超急性期脑梗死价值分析 [J]. 中国CT和MRI杂志, 2021, 19(4): 10-12.
8
朱子煜, 王祖华, 孙文迪, 等. 醒脑静注射液联合长春西汀注射液治疗对老年急性脑梗死患者认知功能障碍及CysC、hs-CRP水平的影响 [J]. 中国老年学杂志, 2021, 41(10): 2035-2038.
9
Cui B, Yang DD, Zheng WM, et al. Plaque enhancement in multi-cerebrovascular beds associates with acute cerebral infarction [J]. Acta Radiol, 2021, 62(1): 102-112.
10
Wang YW, Zhang GM. New silent cerebral infarction in patients with acute non-cerebral amyloid angiopathy intracerebral hemorrhage as a predictor of recurrent cerebrovascular events [J]. Med Sci Monit, 2019, 25(3): 418-426.
11
Suzuki H, Kanamaru H, Kawakita F, et al. Cerebrovascular pathophysiology of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage [J]. Histol Histopathol, 2021, 36(2): 143-158.
12
庞旭阳, 郝晓静, 郭宏盛, 等. 丁苯酞联合低剂量阿替普酶治疗急性脑梗死的疗效及对患者神经内分泌因子的影响 [J]. 现代生物医学进展, 2021, 21(3): 562-566.
13
王卓. 奥扎格雷联合阿替普酶治疗急性脑梗死的疗效及对纤溶功能的影响 [J]. 血栓与止血学, 2021, 27(1): 39-41.
14
翟明明, 邹俊杰, 李昭盈. 复方脑肽节苷脂联合依达拉奉治疗急性脑梗死的疗效及其对血清S100β、NSE、8-iso-PGF2α和MDA水平的影响 [J]. 药物评价研究, 2021, 44(5): 1060-1065.
15
陈宜德, 江凌翔, 卓徐鹏, 等. 通心络胶囊联合依达拉奉治疗老年急性脑梗死的疗效及对神经功能和血脂的影响 [J]. 中国老年学杂志, 2021, 41(5): 930-933.
16
薛亚妮, 刘瑞, 陈彭, 等. 依达拉奉注射液联合阿替普酶静脉溶栓治疗急性脑梗死临床疗效观察 [J]. 陕西医学杂志, 2021, 50(6): 731-734.
17
王世昌, 侯香竹, 孟秀君, 等. 血浆D-二聚体与急性脑梗死患者NIHSS评分的相关性及其影响因素分析 [J]. 中国血液流变学杂志, 2020, 30(1): 40-43.
18
杨小蓉, 蔡祥胜, 卢汉威, 等. 急性脑梗死患者CYP2C19基因多态性与纤维蛋白原及D-二聚体相关性研究 [J]. 检验医学与临床, 2021, 18(2): 149-151, 155.
19
吴章松, 陈然, 徐菲, 等. NLR、PLR、hs-CRP、Hb、D-D与急性脑梗死非溶栓治疗后出血性转化的相关性分析 [J]. 临床和实验医学杂志, 2021, 20(1): 22-25.
20
汪小玲, 刘永强, 张善弟. HCY、hs-CRP、Cys-C、FIB与急性脑梗死患者的关系 [J]. 贵州医药, 2020, 44(7): 1143-1144.
21
Wang J, Zhang YZ, Xu F. Function and mechanism of microRNA-210 in acute cerebral infarction [J]. Exp Ther Med, 2018, 15(2): 1263-1268.
22
李效丽. 进展型脑梗死患者miRNA的表达水平及临床意义 [J]. 国际神经病学神经外科学杂志, 2020(2): 127-131.
[1] 张启龙, 柳亿, 卢会丽, 罗慧, 李成林, 王菁, 王辉. 奥妥珠单抗治疗磷脂酶A2受体相关膜性肾病的疗效与安全性:单中心回顾性分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 379-384.
[2] 王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[3] 莫淇舟, 苏劲, 黄健, 李健维, 李思宁, 柳建军. 智能控压输尿管软镜碎石吸引取石术在直径10~25 mm上尿路结石中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 497-502.
[4] 李义亮, 苏拉依曼·牙库甫, 麦麦提艾力·麦麦提明, 克力木·阿不都热依木. 机器人与腹腔镜食管裂孔疝修补术联合Nissen 胃底折叠术短期疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 512-517.
[5] 周艳, 李盈, 周小兵, 程发辉, 何恒正. 不同类型补片联合Nissen 胃底折叠术修补食管裂孔疝的疗效及复发潜在危险因素[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 528-533.
[6] 王小琴, 汪丽, 崔建英. 无张力疝修补术治疗慢性肾功能衰竭合并腹股沟疝患者的疗效[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 538-542.
[7] 詹济玮, 蔡柳春, 温琼娜, 郭石生, 温春妹, 温鹤明. 布地格福联合噻托溴铵治疗AECOPD 的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 823-826.
[8] 魏孔源, 仵正, 王铮, 黎韡. 机器人胰腺中段切除后远端胰腺消化道不同重建方式初探[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 295-300.
[9] 梁艳娉, 列诗韵, 王艺穗, 吴晓瑛, 林颖. 基于内镜操作细节记录系统构建胃底静脉曲张内镜下组织胶注射术的标准化管理方案[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 705-709.
[10] 陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[11] 史彬, 司远. 益气和络方联合缬沙坦治疗气阴两虚兼血瘀证IgA 肾病的疗效观察[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 306-312.
[12] 韩俊岭, 王刚, 马厉英, 连颖, 徐慧. 维生素D 联合匹维溴铵治疗腹泻型肠易激综合征患者疗效及对肠道屏障功能指标的影响研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 560-564.
[13] 阳跃, 庹晓晔, 崔子豪, 欧阳四民, 林海阳, 胡景宇, 胡银, 李涛, 赵景峰, 郝岱峰, 冯光. 改良“阅读者”皮瓣修复骶尾部压疮的疗效[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 751-755.
[14] 穆巴拉克·伊力哈, 徐霁华, 鲁明. 急性轻型卒中微量脑出血误诊病例的临床特点及影像学表现分析[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 441-445.
[15] 克地尔牙·马合木提, 胡波, 杨琼, 闫素, 胡岚卿, 高沛沛, 姚恩生. 依达拉奉右莰醇对急性脑梗死后认知功能障碍的疗效观察[J/OL]. 中华脑血管病杂志(电子版), 2024, 18(05): 459-466.
阅读次数
全文


摘要